FDA Approves Psilocybin for Treatment-Resistant Depression

The UK life science company COMPASS Pathways receives FDA approval for a clinical trial using psilocybin to treat treatment-resistant depression.

August 2018

COMPASS Pathways receives US Food and Drug Administration (FDA) approval for clinical trials using psilocybin to treat treatment-resistant depression (TRD). Research sites in the UK, Canada, and the Netherlands have already received regulatory approval. Across all the sites, 215 patients with TRD will take part in the study. Phase III trials will follow if this study is successful.